In two randomised trials looking at the cardiovascular outcomes of finerenone, findings suggested cardiovascular and kidney benefits in people with type 2 diabetes and chronic kidney disease,4, 5 while several randomised trials suggested benefits of tirzepatide in weight loss and quality of life.6, 7, 8, 9, 10 A recent large non-industry funded trial has provided insight regarding older drugs for diabetes treatment, including sulfonylureas and basal insulin, by comparing their long term cardiovascular effects with liraglutide, a GLP-1 receptor agonist.11, 12, 13. The gene discussed is GLP1R; the disease is diabetes mellitus.